Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track CATX with free AI briefings, catalyst countdowns, and dilution alerts.

CATX · Perspective Therapeutics, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$201.7M Cash on Hand
23.3mo Cash Runway
Follow CATX by email Get an email when CATX reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CATX, unsubscribe in one click. Privacy

📣 What CATX Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
[203Pb]Pb-PSV359 Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT06710756 Recruiting
[203Pb]VMT-α-NET Neuroendocrine Tumors Unresectable Phase 1/2 · NCT05636618 Recruiting
Lead Pb 203-VMT01 Recurrent Melanoma (Skin) Phase 1/2 · NCT05655312 Recruiting
[212Pb]Pb-PSV359 Pancreatic Ductal Adenocarcinoma Phase 1/2 · NCT06710756 Recruiting
[212Pb] VMT-α-NET Neuroendocrine Tumors Unresectable Phase 1/2 · NCT05636618 Recruiting
Lead Pb 212-VMT01 Recurrent Melanoma (Skin) Phase 1/2 · NCT05655312 Recruiting
Gallium Ga 68-VMT02 Melanoma (Skin) Phase 1 · NCT04904120 Completed

Also used in these trials (approved or third-party drugs, not CATX's own candidates): Nivolumab.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

CATX holds $201.7M in cash and short-term investments (as of Sep 30, 2026) and burns about $26M/quarter from operations, an estimated runway of 23.3 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 48 · Elevated

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when CATX files for a raise →

👥 Who Owns CATX

Insiders 19.6% Other 5%+ holders 17.6% Institutions (166 holders) 62.8% Public and other holders 0%
HolderTypeShares% of sharesAs of
Lantheus Holdings, Inc.
10% owner
Insider 11,563,425 9.58% 2026-09-01
Lantheus Alpha Therapy, LLC
10% owner
Insider 11,273,364 9.34% 2026-09-03
Chen Yu 5%+ holder (13G) 7,915,567 6.55% 2026-02-03
BlackRock, Inc. Institution (13G, 5%+) 7,776,940 6.44% 2026-06-30
Qatar Investment Authority 5%+ holder (13G) 7,073,308 5.86% 2026-02-04
Commodore Capital LP Institution (13G, 5%+) 6,598,046 5.46% 2026-09-30
Millennium Management LLC 5%+ holder (13G) 6,316,545 5.23% 2026-08-07
Avidity Partners Management LP Institution (13G, 5%+) 6,049,999 5.01% 2026-02-20
Lori A Woods
Director · +100,000 options
Insider 212,017 0.18% 2026-11-12
Markus Puhlmann
Chief Medical Officer · +315,000 options
Insider 178,542 0.15% 2026-11-11
Robert F III Williamson
Director · +100,000 options
Insider 143,744 0.12% 2026-11-12
Johan M. Spoor
Chief Executive Officer, Director · +1.39M options
Insider 134,683 0.11% 2026-11-11

Share count 120,758,815 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full CATX picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CATX and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.